Are you Dr. Skolnik?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 57 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
3401 Civic Center Blvd
Childrens Hospital of Philadelphia Hemonc
Philadelphia, PA 19104Phone+1 215-590-3535Fax+1 215-590-3992
Summary
- Dr. Jeffrey Skolnik, MD is a pediatric hematologist/oncologist in Philadelphia, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania. He is affiliated with Children's Hospital of Philadelphia.
Education & Training
Children's Hospital of PhiladelphiaFellowship, Pediatric Hematology/Oncology, 2002 - 2005
Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 1999 - 2002
New York University School of MedicineClass of 1999
Certifications & Licensure
PA State Medical License 2002 - 2024
Clinical Trials
- Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma Start of enrollment: 2007 Apr 01
- Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877 Start of enrollment: 2007 Apr 01
- A Pharmacokinetic Study of Actinomycin-D and Vincristine in Children With Cancer Start of enrollment: 2004 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsChanging incentives to ACCELERATE drug development for paediatric cancer.Teresa de Rojas, Pamela Kearns, Patricia Blanc, Jeffrey Skolnik, Elizabeth Fox
Cancer Medicine. 2023-04-01 - 26 citationsPhase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid I...Robert H. Vonderheide, Kimberly A. Kraynyak, Anthony F. Shields, Autumn J. McRee, Jennifer Johnson
Journal for Immunotherapy of Cancer. 2021-07-01 - 4 citationsToxicity and pharmacokinetics of actinomycin-D and vincristine in children and adolescents: Children's Oncology Group Study ADVL06B1.Jeffrey M. Skolnik, David Hall, Donald A. Barkauskas, Ganesh S. Moorthy, Thomas R. Larson
Cancer Chemotherapy and Pharmacology. 2021-05-22
Press Mentions
INOVIO Announces Dosing of First Subject in Phase 1/2 Clinical Trial for INO-3107, Its DNA Medicine to Treat a Rare Disease Recurrent Respiratory Papillomatosis (RRP)November 23rd, 2020- INOVIO Presents Clinical Results of Its DNA Medicines INO-5401 + INO-9012 in Novel Combination with PD-1 Inhibitor Libtayo® (Cemiplimab) in the Treatment of Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 2020 Annual MeetingNovember 20th, 2020
Inovio Receives Authorization from the U.S. FDA to Begin Phase 1/2 Clinical Trial for INO-3107, a DNA Medicine to Treat a Rare Disease -- Recurrent Respiratory Papillomatosis (RRP)February 10th, 2020- Join now to see all
